Related Experiment Video
Updated: Jan 9, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Natural Products as Potential Therapeutic Candidates for Diabetic Kidney Disease: Molecular Mechanisms, Translational
Manqi Guo1, Lihua Ni1, Xiaoyan Wu1,2
1Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Abstract:
Diabetic Kidney Disease (DKD) is one of the primary causes of chronic kidney disease. However, existing clinical interventions remain insufficiently effective in halting its progression, highlighting the need to explore novel therapeutic approaches. In recent years, natural products such as Abelmoschus manihot have shown growing potential in lowering urinary protein. Building on this background, this paper systematically summarizes preclinical evidence that certain natural substances ameliorate DKD by targeting key pathogenic mechanisms, including inflammation and oxidative stress. It also contrasts the pros and cons of natural medicines with existing therapies, while further investigating advanced pharmaceutical technologies for the translation of natural medicines into clinical applications. However, the clinical translation of natural medicines currently confronts multiple challenges, including small sample sizes, insufficient follow-up periods, individual heterogeneity, and insufficient accumulation of safety data. Therefore, future efforts should prioritize the in-depth exploitation of medicinal plant resources and their clinical translation, with a focus on enhancing high-quality translational clinical studies. This strategy seeks to provide novel insights and practical solutions for treating DKD.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Kidney Transplant I: Introduction
Chronic Kidney Disease IV: Nursing Management
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...